UPDATE! New Permanent J Code for SAPHNELO (anifrolumab-fnia) injection, for intravenous use, 300 mg/2mL
The Centers for Medicare and Medicaid Services (CMS) assigned SAPHNELO a permanent J code (J0491) effective for dates of service on or after April 1, 2022.
Effective April 1, 2022, rheumatology practices administering SAPHNELO™ (anifrolumab-fnia) should use the following billing code for accurate reimbursement and documentation:
- Code: J0491
- Description: Injection, Anifrolumab-fnia, 1 mg
- Vial Size: 300 mg/2 mL single-dose vial
- Billing Units: 300 units
- NDC: 00310-3040-00
Each rheumatology practice provider is responsible for ensuring accurate and compliant coding based on patient medical records. We encourage Rheumatology Practice Managers to contact payers to confirm code adoption and approved usage prior to submitting claims.
For additional assistance with coding and reimbursement questions, contact AstraZeneca Access 360™ at 1-866-SAPHNELO or visit MyAccess360.com.
Stay informed to ensure your rheumatology practice maintains compliance and maximizes reimbursement.
